New UK Clinical Trial Confirms CBD Effective for Generalised Anxiety

Results from a significant UK clinical trial have confirmed that cannabidiol is effective in reducing the symptoms of generalised anxiety disorder, adding to a growing body of evidence that supports the use of cannabis-based medicines in mental health treatment pathways.

Trial Design and Results

The double-blind, placebo-controlled study followed 280 adult participants diagnosed with generalised anxiety disorder over a 12-week treatment period. Participants receiving standardised CBD oral preparations showed statistically significant reductions in anxiety scores compared to the placebo group, with the most pronounced improvements seen at weeks eight and twelve.

• 62% of CBD-treated participants reported a clinically meaningful reduction in symptoms
• Side effect profile was favourable, with mild fatigue reported in fewer than 10% of participants
• No serious adverse events were recorded in the CBD group
• Benefits were sustained at a four-week follow-up assessment

Clinical Implications

Anxiety disorders are among the most common mental health conditions in the UK, affecting an estimated 6 million adults. Current first-line treatments include cognitive behavioural therapy and SSRI medications, but a significant proportion of patients do not respond adequately to these approaches. The trial results suggest CBD could offer a viable alternative for this population.

Patients seeking access to clinically validated CBD should pursue a formal prescription through a licensed clinic. Our anxiety condition guide outlines the current evidence and prescribing criteria. You can also find a specialist through our clinic directory or read our prescription guide. A range of CBD-dominant products currently available in the UK are listed in our strain directory.